This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Imel, E. A. Articles by Econs, M. J. Search for Related Content PubMed PubMed Citation Articles by Imel, E. A. Articles by Econs, M. J. Related Collections Calcium and Bone Metabolism Endocrine Oncology

Sensitivity of Fibroblast Growth Factor 23 Measurements in Tumor-Induced Osteomalacia

Departments of Medicine (E.A.I., M.P., S.L.H., M.J.E.), Pediatrics (E.A.I.), and Medical and Molecular Genetics (M.J.E.), Indiana University School of Medicine, Indianapolis, Indiana 46202; Childrens Hospital Los Angeles (P.P.), University of Southern California, Keck School of Medicine, Los Angeles, California 90027; University of Texas Southwestern Medical Center at Dallas (H.J.H.), Dallas, Texas 75390; Department of Pediatrics (L.M.W.), University of Ottawa, Ottawa, Ontario, Canada K1H 8L1; All Children’s Hospital (D.S.), University of South Florida College of Medicine, Tampa, Florida 33701; Department of Endocrinology (M.K.), University Hospital of Odense, DK-5000 Odense C, Denmark; Beth Israel Medical Center (P.R.), Albert Einstein School of Medicine, Bronx, New York 10003; Department of Veterans Affairs (M.Z.), New Jersey Health Care System, Lyons, New Jersey 07939; Department of Internal Medicine (A.D.), University of Virginia, Charlottesville, Virginia 22908; Internal Medicine Specialties (E.D.), Milwaukee, Wisconsin 53202; Circolo and Fondazione Macchi Hospital (G.C.), 21100 Varese, Italy; Endocrine-Diabetes Center (J.L.S.), St. Luke’s Medical Center, Milwaukee, Wisconsin 53215; and Department of Endocrinology (E.H.H.), Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands

Address all correspondence and requests for reprints to: Michael Econs, M.D., Indiana University School of Medicine, 541 North Clinical Drive, Clinical Building 459, Indianapolis, Indianapolis 46202. E-mail: mecons{at}iupui.edu.

Context: Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome of hypophosphatemia, decreased renal phosphate reabsorption, normal or low serum 1,25-dihydryxyvitamin-D concentration, myopathy, and osteomalacia. Fibroblast growth factor 23 (FGF23) is a phosphaturic protein overexpressed in tumors that cause TIO and is, at least partly, responsible for the manifestations of TIO.

Objective: The objective of this study was to determine the sensitivity of FGF23 measurements in TIO.

Design: FGF23 concentrations were measured on stored samples with three ELISAs.

Setting: This study was conducted at subspecialty referral centers.

Patients: Twenty-two patients with suspected TIO, 13 with confirmed tumors, were studied.

Interventions: There were no interventions in this study.

Main Outcome Measure: FGF23 concentration was the main outcome measure of this study.

Results: Elevated FGF23 concentrations were detected using the Immunotopics C-terminal assay in 16 of 22 TIO patients (for a sensitivity of 73%), the Immunotopics Intact assay in five of 22 patients (sensitivity, 23%), and the Kainos Intact assay in 19 of 22 patients (sensitivity, 86%). In the 13 patients with confirmed tumors, the sensitivity was higher with all assays: 92% for the Immunotopics C-terminal assay, 38% for the Immunotopics Intact assay, and 100% for the Kainos assay.

Conclusion: The Kainos Intact assay was the most sensitive, followed by the Immunotopics C-terminal assay. The findings of normal FGF23 concentrations in some patients with TIO may indicate that FGF 23 is not responsible for the hypophosphatemia in these patients or that FGF23 secretion by some tumors is partially responsive to serum phosphate. Normal FGF23 concentrations should be interpreted in relation to the serum phosphate and 1,25-dihydryxyvitamin-D concentrations.

This article has been cited by other articles:

				A. L. Tencza, S. Ichikawa, A. Dang, D. Kenagy, E. McCarthy, M. J. Econs, and M. A. Levine Hypophosphatemic Rickets with Hypercalciuria due to Mutation in SLC34A3/Type IIc Sodium-Phosphate Cotransporter: Presentation as Hypercalciuria and Nephrolithiasis J. Clin. Endocrinol. Metab., November 1, 2009; 94(11): 4433 - 4438. [Abstract] [Full Text] [PDF]

				M. A. I. Mirza, T. Hansen, L. Johansson, H. Ahlstrom, A. Larsson, L. Lind, and T. E. Larsson Relationship between circulating FGF23 and total body atherosclerosis in the community Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3125 - 3131. [Abstract] [Full Text] [PDF]

				B. J. Schouten, P. J. Hunt, J. H. Livesey, C. M. Frampton, and S. G. Soule FGF23 Elevation and Hypophosphatemia after Intravenous Iron Polymaltose: A Prospective Study J. Clin. Endocrinol. Metab., July 1, 2009; 94(7): 2332 - 2337. [Abstract] [Full Text] [PDF]

				A. C Heijboer, M. Levitus, M. G Vervloet, P. Lips, P. M t. Wee, H. M Dijstelbloem, and M. A Blankenstein Determination of fibroblast growth factor 23 Ann Clin Biochem, July 1, 2009; 46(4): 338 - 340. [Abstract] [Full Text] [PDF]

				K. Wesseling-Perry, R. C. Pereira, H. Wang, R. M. Elashoff, S. Sahney, B. Gales, H. Juppner, and I. B. Salusky Relationship between Plasma Fibroblast Growth Factor-23 Concentration and Bone Mineralization in Children with Renal Failure on Peritoneal Dialysis J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 511 - 517. [Abstract] [Full Text] [PDF]

				M. Mannstadt, C. Lorente, and H. Juppner Rapid Detection of Intact FGF-23 in Tumor Tissue from Patients with Oncogenic Osteomalacia Clin. Chem., July 1, 2008; 54(7): 1252 - 1254. [Full Text] [PDF]

				F. M Hannan, N. A Athanasou, J. Teh, C. L M H Gibbons, B. Shine, and R. V Thakker Oncogenic hypophosphataemic osteomalacia: biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1 Eur. J. Endocrinol., February 1, 2008; 158(2): 265 - 271. [Abstract] [Full Text] [PDF]

				H. Dobbie, R. J. Unwin, N. J. R. Faria, and D. G. Shirley Matrix extracellular phosphoglycoprotein causes phosphaturia in rats by inhibiting tubular phosphate reabsorption Nephrol. Dial. Transplant., February 1, 2008; 23(2): 730 - 733. [Abstract] [Full Text] [PDF]

				S. Liu and L. D. Quarles How Fibroblast Growth Factor 23 Works J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1637 - 1647. [Abstract] [Full Text] [PDF]

				S. Ichikawa, V. Guigonis, E. A. Imel, M. Courouble, S. Heissat, J. D. Henley, A. H. Sorenson, B. Petit, A. Lienhardt, and M. J. Econs Novel GALNT3 Mutations Causing Hyperostosis-Hyperphosphatemia Syndrome Result in Low Intact Fibroblast Growth Factor 23 Concentrations J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1943 - 1947. [Abstract] [Full Text] [PDF]

				S. Ichikawa, E. A. Imel, A. H. Sorenson, R. Severe, P. Knudson, G. J. Harris, J. L. Shaker, and M. J. Econs Tumoral Calcinosis Presenting with Eyelid Calcifications due to Novel Missense Mutations in the Glycosyl Transferase Domain of the GALNT3 Gene J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4472 - 4475. [Abstract] [Full Text] [PDF]